MaxCyte (MXCT) Set to Announce Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) will be releasing its earnings data after the market closes on Tuesday, August 6th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company had revenue of $11.34 million during the quarter, compared to analyst estimates of $7.75 million. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $4.37 on Monday. The firm has a market capitalization of $458.06 million, a PE ratio of -12.49 and a beta of 1.42. The business has a 50-day moving average of $4.46 and a two-hundred day moving average of $4.44. MaxCyte has a 12 month low of $2.45 and a 12 month high of $5.55.

Analyst Upgrades and Downgrades

Separately, Stephens restated an “overweight” rating and set a $11.00 price objective on shares of MaxCyte in a research note on Tuesday, April 23rd.

Insider Buying and Selling at MaxCyte

In other news, CEO Maher Masoud purchased 29,557 shares of the stock in a transaction dated Friday, June 7th. The shares were bought at an average cost of $4.87 per share, for a total transaction of $143,942.59. Following the transaction, the chief executive officer now owns 29,557 shares in the company, valued at $143,942.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Maher Masoud purchased 29,557 shares of MaxCyte stock in a transaction on Friday, June 7th. The stock was bought at an average price of $4.87 per share, with a total value of $143,942.59. Following the completion of the transaction, the chief executive officer now directly owns 29,557 shares of the company’s stock, valued at $143,942.59. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Joseph Johnston sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $3.99, for a total value of $39,900.00. Following the transaction, the director now directly owns 141,950 shares of the company’s stock, valued at approximately $566,380.50. The disclosure for this sale can be found here. Insiders have sold 59,864 shares of company stock valued at $245,012 in the last quarter. Corporate insiders own 3.00% of the company’s stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.